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Abstract Goals of work: Testicular
cancer (TC) affects young men in
the prime of life. The excellent
prognosis and an increasing inci-
dence have led to a growing number
of testicular cancer survivors (TCSs).
The aim of this review was to sum-
marize and discuss research findings
on the quality of life (QOL) of TCSs
in terms of physical, psychological,
and social well-being. Patients and
methods: Literature databases were
used to identify studies published
between 1980 and 2003. A quality
assessment using methodological and
treatment-related criteria was per-
formed to distinguish stronger- from
poorer-quality studies. Main results:
Twenty-three studies met the inclu-
sion criteria. Quality assessment
showed that seven studies were
qualitatively stronger. The majority
of TCSs in both stronger and poorer
quality studies reported a good QOL.
Prospective and retrospective studies
showed that QOL after completion of
treatment increased and negative
consequences of TC on life decreased
compared to the situation directly
after diagnosis. The stronger-quality
studies reported mainly on physical
and psychological well-being but
did not examine social well-being
and the impact of treatment-related
characteristics comprehensively.
Conclusions: Both stronger- and
poorer-quality studies indicate that
the majority of TCSs experience a
good QOL, but the shortcomings on
both the methodological and content
level prevent us from drawing such a
conclusion. Additional research with
strong designs is needed to gain
clearer insight into the QOL of TCSs
as a group and of individuals at risk
for physical, psychological, and so-
cial problems.
Keywords Testicular cancer
survivors · Quality of life · Literature
review
Introduction
Men between 15 and 45 years are in the prime of life.
Major issues that concern them are career, interpersonal
relationships, and starting a family. Life-threatening ill-
nesses and the possibility of dying do not fit their outlook
in this period of life [28, 50]. Nevertheless, a small per-
centage of these men will develop the most common neo-
plasm in young men: testicular germ cell cancer (TC).
Despite increases in incidence, TC is an uncommon dis-
ease. It accounts for approximately 1% of all malignan-
cies in men, although the incidence varies according to
geographical area and race. Compared to other malignan-
cies, the age distribution of TC is unusual in that the
incidence declines with advancing age. Since the intro-
duction of cisplatin-based polychemotherapy in the late
1970s, (disseminated) TC has become one of the most
curable malignancies [8, 14].
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There are two histological types of TC: seminomatous
and nonseminomatous tumors. Treatment for TC depends
on histological type and stage of disease. Nowadays,
treatment for stage I nonseminomatous disease consists
of surgical removal of the affected testis (orchidectomy)
and surveillance or nerve-sparing retroperitoneal lymph-
node dissection. Initial treatment for disseminated disease
(stages II–IV) is cisplatin-based polychemotherapy fol-
lowed by resection of residual retroperitoneal or pulmo-
nary tumor mass if necessary. Patients with a stage I and
IIA/B seminoma are treated with orchidectomy and ra-
diotherapy, while those with stages IIC–IV are treated
with chemotherapy [8].
At present, almost 90% of testicular cancer patients
can be cured with existing treatment modalities. Owing to
the excellent prognosis, the young age and an increas-
ing incidence, the number of testicular cancer survivors
(TCSs) is growing. These men may have an additional life
expectancy of perhaps 50 years after treatment and con-
sequently they will have to face possible sequel of diag-
nosis and treatment for the rest of their lives [42]. The
first reports that dealt with the quality of life (QOL,
an umbrella term for physical, psychological, and social
well-being) of TCSs appeared a few years after the break-
through in medical treatment. Since that time, studies
have been performed on the consequences of the experi-
ence with TC for a variety of QOL domains. Unfortu-
nately, a critical overview of the current state of knowl-
edge on the QOL of survivors has not been published at
this point in time, while the group of survivors is growing
and the literature continuous to expand. A thorough re-
view of the literature may guide clinicians when provid-
ing patients with information on possible short- and long-
term effects of the experience with TC on their lives, and
it may provide insight into areas that need more research.
The aims of this study were: (1) to review the literature on
the QOL (physical, psychological, and social well-being)
of TCSs, and (2) to assess the impact of treatment-related
characteristics, such as time since diagnosis and type of
treatment, on the QOL of survivors.
Patients and methods
MEDLINE, EMBASE, PsycINFO and CancerLIT databases were
used to identify relevant publications, as were the references of
these papers. Keywords were “testicular cancer,” “testicular neo-
plasm,” “neoplasm,” “cancer,” “cancer survivors,” “survivors,” and
“quality of life.” To encompass a wide range of QOL outcomes, we
also used the following descriptor terms: “depression,” “anxiety,”
“distress,” “marital functioning,” “social functioning”, and “work-
related problems.” Selection criteria were: (1) papers published in
English between 1980 and October 2003, (2) studies on patients
with TC who were in complete remission, (3) studies on physical,
psychological, and social well-being, and (4) papers in which
subgroups of TCSs could be clearly identified. Operationalizations
of physical, psychological, and social well-being were based on the
literature on QOL in cancer survivors [3, 10, 24, 26, 32, 51]. For
physical well-being, the focal points were subjective perceptions of
general health, fatigue, and body image. Physical side-effects of the
treatment for TC were not included because these aspects have
been addressed in previous studies [8, 25, 34, 43]. For psycholog-
ical well-being, distress (including anxiety and depression), health
worries, and psychological well-being were chosen from the variety
of possible operationalizations. In addition, distress about infertility
due to treatment was evaluated. For social well-being, the focal
points were marital functioning, social support, and functional life.
Although sexual well-being is also an important outcome variable,
it was not included, because this issue has received extensive at-
tention recently [29, 36].
Methodological aspects were not used as an inclusion criterion,
because the aim was to make an inventory of the literature on the
QOL of TCSs. Studies with methodological shortcomings, such as
nonstandardized questionnaires and small sample sizes, may have
detected relevant and valuable (site-specific) information that
strong methodological studies overlooked. These studies may be of
value in providing directions for future research. However, this
decision not to use methodological aspects as selection criteria
may decrease the power of the findings in the current study [31].
Therefore, it was decided to assess the quality of the studies first.
There is no gold standard to determine which criteria should be
used in quality assessments [2], but one critical issue is the internal
validity of the studies, which is derived from study procedures and
design. Furthermore, with regard to the research questions of this
review, we considered treatment-related aspects to be important
criteria as well. Therefore, the following methodological and
treatment-related aspects were used for quality assessment: design,
sample size, use of comparison groups, measurement instruments,
type of treatment, and time since diagnosis.
It needs to be pointed out that results of individual studies in-
volving comparison of groups or correlational analyses are only
reported when they were statistically significant at a level of p 
0.05 in the analyses.
Results
A total of 23 studies met the inclusion criteria. Table 1
shows the data on the aspects that were considered in
the quality assessment. Quality assessment revealed that
studies differed greatly in quality. Seven studies were
considered as stronger [19, 20, 27, 40, 41, 42, 47], be-
cause on the whole, these studies used suitable designs,
had adequate sample sizes, used validated questionnaires
and comparison groups (with exception of the two
prospective studies) [20, 47], and had large ranges in time
since treatment (with exception of the two prospective
studies). Furthermore, these studies considered time since
treatment in their analyses, whereas in total, only nine
studies investigated whether time since diagnosis was
related to one of the outcome variables [7, 11, 16, 19, 27,
35, 39, 40, 41]. None of these studies found a relationship
between time since diagnosis and any of the dimensions
of QOL. Five of the qualitatively stronger studies were
published recently (between 2000 and 2003). However,
the remaining two stronger studies were published in
1989, indicating that the poorer-quality studies were not
necessarily the earlier studies.
Because it is probable that the findings from the





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































best answer the research questions of this review, it was
decided to discuss the results of these studies first. The
results of the remaining studies will be related to these
seven studies, and possible differences in results will be
explained using the quality criteria.
One last remark should be made about type of treat-
ment. Eight retrospective/cross-sectional studies included
both TCSs that had been treated before and after 1978
(when cisplatin-based chemotherapy was introduced) [4,
11, 12, 16, 18, 35, 39, 40]. However, it was not possible
to compare the two time periods, because the studies did
not consider changes due to developments in treatment
in their analyses. Furthermore, most studies only con-
sidered treatment-related characteristics as independent
variables. Other factors that could possibly influence the
outcome, such as sociodemographic characteristics and
the patient’s support system, were usually not considered.
All factors reported on by the studies that have a sig-




Four of the qualitatively stronger studies reported on
health perception. Prospectively, it was shown that physi-
cal functioning of TCSs treated with chemotherapy re-
covered to baseline levels during the 2 years following
diagnosis [20]. At time of study, over 70% of TCSs as-
sessed their general health as good [41], and perceived
their health and physical functioning as equal to that of
age-matched healthy men [27, 41]. None of these quali-
tatively stronger studies compared treatment groups.
The poorer-quality studies reported comparable find-
ings. Several studies reported that TCSs experienced no
change in health status compared to the pretreatment
situation, and between 63 and 90% assessed their general
health as good [4, 7, 11, 21, 46]. Two studies found no
differences in perceived health and physical functioning
between TCSs and age-matched healthy men or men
treated for Hodgkin’s disease [7, 15]. However, one study
that did not use a validated questionnaire reported that
TCSs assessed their own health as better than that of
controls [30]. No differences in physical well-being were
found between men treated with different treatment
modalities [4, 30, 46].
Fatigue
Fatigue was studied relatively comprehensively by the
qualitatively stronger studies. Prospectively, an improve-
ment of fatigue was reported in TCSs treated with che-
motherapy, although 19% experienced deterioration in fa-
tigue 2 years after treatment [41]. Eighty-four percent
experienced no chronic fatigue at time of study [19]. Two
studies found that fatigue scores did not differ from those
of age-matched healthy men or the general population
[27, 42], but Fossa et al. [19] reported that TCSs younger
than 30 years experienced more fatigue than the same age
cohort of the general population. Furthermore, it was
found that TCSs who experienced more fatigue reported a
poorer overall QOL [27]. Fatigue was associated with
pretreatment distress, morbidity, lower educational level,
older age, comorbidity, and higher levels of depression
and anxiety [19]. Differences between treatment groups
were not found [19, 27].
Overall, results of the poorer-quality studies were in
line with those of the qualitatively stronger studies. Two
studies reported that most TCSs felt energetic (75% [21]
and 82% [11]), although it took an average of 9 months
for energy levels to return to normal [21]. Compared to
men treated for Hodgkin’s disease, energy levels returned
to normal in more TCSs, and they reported less fatigue at
the time of data collection [7, 18]. Fatigue scores of TCSs
did not differ from those of norm groups or age-matched
healthy men [21, 22, 39]. In contrast with the qualitatively
stronger studies, one study reported that men treated for
seminoma experienced more fatigue than men treated for
nonseminoma [21], but this last study had a much smaller
sample size than the stronger studies [19, 27].
Body image
The loss of a testicle, which is an organ associated with
masculinity and sexuality, may result in an impaired body
image [49]. The body image of TCSs returned to normal
in the course of time, and at the time of data collection,
most TCSs in the qualitatively strong studies did not re-
port feeling less attractive (77.3% [42] and 84.8% [41]) or
less masculine than before TC (79%) [20]. Men who felt
less attractive had lower scores in most health-related
QOL domains, reported more fatigue, and were less sat-
isfied with their family life than those who did not feel
less attractive [41, 42]. These results were supported by
the poorer-quality studies, which found that the majority
of TCSs had no changed body image (56–94%) [7, 9, 11,
35]. In addition, these studies reported that the body im-
age of TCSs did not differ from that of men treated for
Hodgkin’s disease, and their feelings of masculinity were
equal to those of sociodemographically matched men [7,





In the qualitatively stronger studies, the levels of psy-
chological distress experienced by TCSs varied between 9
and 27% [19, 40, 41]. One of these studies reported that
TCSs as a group experienced significantly less distress
than controls [40]. However, Fossa et al. [20] found that
TCSs experienced more anxiety but less depression than
the general population. One study found that a quarter of
the TCSs became more anxious after diagnosis and treat-
ment [40]. The contradictory results may be explained
by the different aspects of distress addressed in these
studies and the use of different validated questionnaires.
None of the qualitatively stronger studies compared treat-
ment modalities.
A study of poorer quality reported that 13% of the
TCSs experienced depression and 16% tension [11]. In
retrospect, TCSs reported more anxiety, depression, and
distress during the first 6 months after diagnosis than male
college students, but levels decreased over time [15, 21,
30, 35]. One study stated that scores did not return to
baseline levels, another study found that 12 months after
diagnosis, TCSs treated with radiotherapy experienced
less distress than male college students [11, 15]. A sig-
nificant number of TCSs experienced more depression
since treatment [4]. Partly in contrast with the results of
Fossa et al. [20], two poorer-quality studies using self-
developed questionnaires reported that TCSs experienced
more anxiety, depression, and psychosocial problems than
age-matched men and controls [15, 30]. Furthermore,
three studies using validated questionnaires but small
sample sizes found no differences in levels of anxiety and
depression between TCSs and age-matched men, psy-
chiatric patients, male college students, and other cancer
patients [21, 22, 39]. In line with Rieker et al. [40], two
studies reported that TCSs experienced less distress than
healthy sociodemographically matched men, male college
students, and psychotherapy patients [7, 21]. In addition,
one study found that men treated with radiotherapy re-
ported more depression, but two other studies showed no
differences between treatment groups [4, 30, 46]. The
small sample sizes of the different treatment groups and
the use of self-developed questionnaires may explain
these contradictory results.
Health worries
Seventeen percent of the TCSs in the qualitatively
stronger study of Fossa et al. [20] reported an increase of
fear of recurrence 2 years after baseline measurement,
whereas anxiety had decreased in 36%. Since their ex-
perience with TC, 19% of TCSs reported more fear of
dying, while 32% reported less fear [40]. None of the
stronger studies reported on differences between treat-
ment modalities in health worries.
In concurrence with Fossa et al. [20], decreases in fear
of recurrence (from 45 to 12%) and in fear of developing
a second primary malignancy (from 50 to 21%) were
reported in the poorer-quality studies, although health
worries were still present in 54–76% of TCSs [4, 18, 21,
35, 46]. TCSs who reported more anxiety and depression
were more afraid of a tumor recurrence, spent more time
worrying about their health, and had more concerns about
their health [35]. One study found no differences in health
worries between men who received different treatment
modalities; a second study reported that radiotherapy pa-
tients worried more about their health after treatment; a
third study showed that men treated with chemotherapy
experienced greater fear of a tumor recurrence than men
treated with radiotherapy [4, 21, 46]. As mentioned ear-
lier, a likely explanation for the contradictory results
between studies that compared treatment groups are the
small sample sizes and the use of nonvalidated ques-
tionnaires to assess health worries.
Fertility distress
TC strikes men at an age when fertility is a major con-
cern. Cancer-treatment modalities are known to result in
infertility [7]. Prospectively, it was found that fertility
distress decreased during the 2 years after treatment in
28% of TCSs, but it increased in 11% [20]. Compared to
sociodemographically matched healthy men, TCSs re-
ported more overall problems with being infertile (5%
compared to 22%) [40]. Infertility distress was reported
most by TCSs with posttreatment ejaculatory dysfunction,
those without children, of younger age, with a lower in-
come, and those treated with chemotherapy and retro-
peritoneal lymph-node dissection (RPLND) [39, 40].
Across the treatment groups, percentages of fertility dis-
tress varied from 11% in the radiotherapy group to 33% in
the men treated with chemotherapy and RPLND [40].
The poorer-quality studies reported that during and
after treatment, TCSs were more anxious about infertility
than before diagnosis, but men who were infertile and
those who were uncertain about their fertility status were
not significantly more depressed and anxious than those
who were fertile [35, 37]. The majority of the 11 TCSs
that were interviewed reported discomfort and regret
about possible infertility [9]. Only one study reported on
fertility distress in men treated for bilateral TC. Surpris-
ingly, these men reported few problems with their fertility
status, but the sample size was small and the study used
one question only to assess fertility distress [18].
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Psychological well-being
Although many QOL studies have shown that cancer and
its treatment have detrimental effects on patient’s lives,
there is a growing awareness that there may also be
positive effects. The prospective studies showed that the
QOL of TCSs improved progressively after orchidectomy
or chemotherapy [20, 47]. At time of study, TCSs and
age-matched men reported a similar QOL, and there were
no differences between treatment modalities [27].
The results of the poorer-quality studies were rather
positive as well. One study found that TCSs reported being
more satisfied with their lives than age-matched men [30],
and two studies reported a similar QOL in TCSs, and
norm-group men, and controls [12, 18]. Over 73% of
TCSs experienced good QOL after treatment [11]. A
positive rather than negative impact was experienced by
over half of the TCSs (exact percentages unknown), while
76% considered that surviving cancer was a worthwhile
achievement [39]. Several positive effects were men-
tioned, including the ability to enjoy oneself, renewed
appreciation of life, emotional growth, and the resetting of
priorities and values [9, 39]. The experience of cancer
benefited the psychological well-being of most patients
treated with chemotherapy (77%) and radiotherapy (82%)
[46]. In one study, men treated with radiotherapy or che-
motherapy reported greater satisfaction with life than men
in the surveillance group, but this result was not confirmed
by another study [4, 30]. Again, a probable explanation for




Treatment for TC is known to have repercussions on
marital functioning [23]. The qualitatively stronger stud-
ies reported that most TCSs did not experience a change
in the relationship with their partner after their experience
with TC [40, 41] and that treatment groups did not differ
in their responses to questions about changes in the part-
ner relationship since treatment [47].
The subject of marital functioning received much more
attention in the poorer-quality studies. Quite similar to
the results of the stronger studies, most of TCSs in these
studies reported that the relationship with their partner
had not changed or had become stronger after their ex-
perience with TC [4, 9, 35, 46]. Anxiety about separation
from the spouse was not a concern before, during, or after
treatment in most TCSs (84–94%), while scores on spouse
importance and quality of communication did not differ
over the course of time. The degree of support from the
spouse increased during treatment as compared to the sit-
uation prior to diagnosis and decreased again afterwards
[37]. In TCSs, of patients who experienced a change in
their partner relationship after TC, most married men in-
dicated that the relationship had strengthened (68%),
whereas 74% of unmarried men reported that it had be-
come strained [39]. TCSs appeared to be more satisfied
with their partner relationship than sociodemographical-
ly matched men [12]. Treatment groups did not differ in
their responses to questions about changes in partner re-
lationships since treatment, although men treated with the
most extensive treatment modality (radiotherapy, che-
motherapy, and/or RPLND) reported less satisfaction with
family life than the other treatment groups [4]. This find-
ing was in line with the qualitatively stronger study.
Single TCSs may have difficulties starting a relation-
ship not only on account of the above-mentioned issues
with infertility, sexual functioning, and altered body im-
age, but also due to the feeling of estrangement from
their peers without a history of cancer. No qualitatively
stronger study considered this issue, and only one poorer-
quality study reported on TCSs who were not involved
with a partner or were not married at the time of their
diagnosis and treatment. This study showed that two out
of the ten patients who got married after treatment found
that having had TC caused difficulties in the marital
process, while 35% of the 28 men who were single at the
time of data collection thought that the cancer experience
would form a problem in planning a marriage [37].
Social support
Only one qualitatively stronger study focussed on social
functioning after TC. This study reported that TCSs ex-
perienced fewer changes in relationships with friends than
sociodemographically matched healthy men [27]. The qual-
itatively poorer studies showed that the experience of TC
did not result in changed relationships with family (66–
93%) and friends (77–95%) [4, 11, 46]. Furthermore, it
was reported that 92% of TCSs were satisfied with the
support they received during treatment [35]. They men-
tioned more “enriching” relationships with family and
friends, although they had become more selective [9].
One study showed no differences between treatment
groups, but another study reported improved relationships
with family and friends in patients treated with chemo-
therapy [4, 46].
Functional life
Long-term side-effects of treatment (such as fatigue, psy-
chosocial problems, and fear of tumor recurrence), may
cause difficulties in resuming work or study after treat-
ment [17]. The qualitatively stronger studies reported that
at the time of data collection, 76–90% of TCSs were
employed [27, 40, 41] and that their employment status
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was no different from that of age-matched healthy men
[27]. Furthermore, Joly et al. [27] reported that TCSs and
controls had similar problems in their professional lives,
although TCSs were less ambitious than controls.
The poorer-quality studies reported more extensively
on functional life. These studies also showed that most
TCSs were employed at the time of data collection (82–
98%) [6, 7, 16, 35, 39]. Their employment status after
treatment appeared to be the same as before [11, 16,
39, 46], and it was better than that of men treated for
Hodgkin’s disease [6]. Over 90% of TCSs who returned
to work perceived no effect on their career mobility, 45%
experienced no effect on their ambition and career plans
(while 26% reported a positive effect), and 52% experi-
enced no effect on their satisfaction with work (while
32% reported more satisfaction) [39]. In line with the
results of Joly et al. [27], two studies found that work and
ambition had become less important since TC, because
men had reorganized their priorities and had adopted a
new philosophy of working to live rather than living to
work [9, 16]. Compared to men treated for Hodgkin’s
disease, TCSs were better able to work at their former
pace [7]. Compared to age-matched controls, TCSs felt
less physically exhausted after a working day and could
maintain significantly better concentration and attention
at work [30].
Small percentages of TCSs reported negative effects
of the cancer treatment on their work satisfaction (16%),
career mobility (10%), ambitions and career planning
(29%), and relationships with supervisors and coworkers
(5–14%), while 12–25% were unable to work at their
former pace, finish tasks, and had problems with con-
centration [6, 7, 16, 39]. In terms of treatment groups,
between 12–31% of men treated with radiotherapy or
chemotherapy reported job loss and loss of job prospects
because of their illness [4, 46]. Deterioration in profes-
sional performance was reported by 17% of the radio-
therapy group and 3% of the other treatment modalities
[37]. Men in the surveillance group were less comfortable
with their work than TCSs treated with chemotherapy or
radiotherapy and had more problems with concentration
and attention at work than TCSs treated with chemo-
therapy. However, another study found no differences
between treatment groups [4, 30]. Men treated with ra-
diotherapy were more satisfied with their work than those
treated with chemotherapy or those in the surveillance
group, and they felt that work was more worthwhile than
those in the surveillance group [4]. There was no differ-
ence between treatment groups with respect to physical
exhaustion after work [4, 30]. All of these poorer quality
studies had serious methodological shortcomings: sample
sizes of the total groups (only two studies included more
than 100 TCSs) and the treatment groups were small, all
studies used nonvalidated questionnaires or question-
naires of which the psychometric qualities were not re-
ported, and no study compared TCSs with sociodemo-
graphically matched healthy men.
Discussion
The goal of this study was to give a comprehensive re-
view of the literature of primary studies examining phys-
ical, psychological, and social well-being of TCSs. A total
of 23 studies, published between 1985 and 2003, met the
inclusion criteria. Because these studies used such a broad
variety of methodologies and research questions, this re-
view was by necessity descriptive. However, a quality
assessment was performed to interpret and explain con-
tradictory results and to increase the power of this review.
Based on methodological and treatment-related criteria,
seven studies appeared to be qualitatively stronger.
Results of both stronger- and poorer-quality studies ap-
peared quite similar. Prospective and retrospective studies
showed that QOL after completion of treatment increased
and that the negative consequences of TC on life de-
creased compared to the situation directly after diagnosis
when a poorer QOL was observed. For example, energy
levels returned to normal, fatigue decreased, and TCSs
became used to their changed body image. Decreases
were found in psychological distress, anxiety, depression,
and fear of tumor recurrence. The stronger-quality studies
paid little attention to social dimension (marital func-
tioning, social support, and functional life) and positive
effects of the experience with TC. Poorer-quality studies
reported that, besides a decrease in negative consequences
of TC on the patients’ lives, the experience of TC seemed
to have positive effects. A considerable proportion of
TCSs reported that they experienced emotional growth,
were appreciating life more, and had stronger relation-
ships with family and friends. Results on functional life
were mainly contradictory.
Based on this summary of the results, one could as-
sume that in general, TCSs experience a good QOL. How-
ever, this could be an arguable assumption because of the
methodological shortcomings of most studies and because
the stronger-quality studies did not investigate all dimen-
sions of QOL with the same extensiveness. Below we
discuss various methodological issues.
Firstly, many studies used a retrospective design to
evaluate the well-being of TCSs and to compare their
well-being before and/or after treatment. Data obtained in
retrospect are less reliable for two reasons: (1) the chance
is great that recall was distorted (selective memory bias),
because 1–36 years had passed between data collection
and diagnosis [13, 31, 39, 41]; (2) under the influence of
certain life events (such as experience with cancer), in-
ternal standards can change (response shift) and cause
people to evaluate new situations according to other
standards [44]. For example, people can become accus-
tomed to a higher level of fatigue, and after a certain
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amount of time, report the same QOL as that prior to the
illness [38, 45]. Such changes in internal standards cannot
be reproduced accurately in retrospective studies. The
only way that conclusions can be drawn from cross-sec-
tional or retrospective studies about the relationship be-
tween TC and QOL is to compare the current QOL of
TCSs to that of a sociodemographically-matched group.
Secondly, a considerable number of studies had no
comparison group. Some studies used norm groups, but
these often differed from TC patients in sociodemo-
graphic areas. In studies that compared TCSs to other can-
cer patients, it often appeared that the other cancer pa-
tients had a poorer prognosis and had received other
forms of treatment.
Thirdly, a wide variety of both validated and nonval-
idated measurement instruments were used to evaluate the
same aspects of QOL, which made it difficult to compare
results. Therefore, some differences in findings may be
due to the different instruments that were used, even if
they were validated measures. In studies that used non-
validated instruments, some variables (e.g., body image)
were measured with only one or two items. This affected
the reliability of study results, and it is not clear whether
their scope is of sufficient depth [33].
Fourthly, descriptive and comparison analysis methods
were generally used, whereas techniques such as regres-
sion analyses would have enabled the identification of
possible risk groups.
Fifthly, in a large proportion of the studies, reliability
and generalizability were affected by small numbers
(fewer than 100 TCSs). A small study group means that
there is insufficient power to determine the possible in-
fluence of demographic and treatment-related variables
[27].
Sixthly, the majority of studies did not correct for
confounding variables such as age, marital status, edu-
cation level, time since diagnosis, treatment modality, and
disease stage, although they aimed to measure the nega-
tive impact of illness or treatment on QOL. To identify
possible groups of men who are at risk of developing
problems, it is essential to control for demographic and
treatment-related variables.
In addition to these methodological issues, the studies
showed limitations in how they applied the treatment-
related variables. Only nine studies considered time since
diagnosis in their analyses, and the categorizations of
treatment modalities were rough. None of the studies re-
flected on changes in treatment over time, which may
have caused a threat to the internal validity.
From a historical point of view, the differences in
methodologies between studies and the methodological
shortcomings of most studies are well explainable. The
earlier studies had to use explorative designs, self-devel-
oped, and nonvalidated questionnaires and could only
focus on short-term sequel of survivorship. In contrast,
the more recent studies could make use of well-validated
and reliable instruments developed over the years. Fur-
thermore, the number of survivors has greatly increased
due to advances in medical treatment, making method-
ologically stronger studies possible. Therefore, it was not
surprising that five of the seven methodologically stron-
ger studies were published between 2000 and 2003, al-
though the poorer-quality studies were not necessarily the
earlier studies.
A problem of studies with methodological shortcom-
ings is that their results may not always concur with re-
ality. This can be illustrated with three examples from this
review. Firstly, it would have been reasonable to expect
that more extensive treatment would cause more short-
and long-term physical and psychosocial side effects. It
may be that the lack of documented effect of treatment
reflects inadequate methodology, lack of adequately pow-
ered and comprehensive studies, and the rough catego-
rizations of treatment modalities. A second example that
illustrates the distorting effect of methodological short-
comings on the outcomes of this review is the wide va-
riety of percentages between studies of TCSs reporting
negative effects. For example, the level of psychological
distress varied between 8% and 27%, while 5% to 29%
were experiencing work-related problems since TC. A
third example is the result that men with bilateral TC have
less fertility issues. There is only one study that states
this, and given the lack of biological rationale for this
observation, it may be regarded as casuistry and not as a
reflection of reality.
As regard to content, more research is needed as well.
The qualitatively stronger studies did not exhaustively
delve into any of the outcome variables, indicating that
more research is needed on all dimensions of QOL but
most of all in the area of social well-being and the impact
of treatment-related characteristics. The poorer-quality
studies provided some directions for future research. In
particular, issues that may be of major concern for young
men dealing with the sequel of cancer diagnosis and treat-
ment, such as body image, fertility issues, intimate rela-
tionships, social support, and work-related issues, need
more attention. Surprisingly few studies attacked these
issues, and all these studies suffered from methodological
shortcomings (nonvalidated questionnaires and small
sample sizes). For example, the effects of TC on casual
relationships and on men who had no partner at the —
time of TC have received very little attention. One study
showed that TC had a negative effect on casual rela-
tionships, whereas the relationship of many married men
with their spouse became stronger. The only study that
investigated whether men who were single at the time of
diagnosis experienced problems with starting a new re-
lationship found that 20% of men reported problems. It
would seem worthwhile to conduct more research into the
effects of TC on casual relationships and on single men,
because TC particularly affects young men who are more
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